Login
Companies $LQDA
$55.25 -$1.12 (1.99%) After hours
Liquidia Corp logo

Liquidia Corp

liquidia.com

What Do They Do?

Sells YUTREPIA, an inhaled treprostinil medicine for people with pulmonary arterial hypertension, and develops inhaled medicines for respiratory and vascular diseases.

How Do They Make Money?

YUTREPIA sales come from supplying specialty pharmacies and a specialty distributor, with sales counted when the product is delivered. Service revenue came from sharing profit on Sandoz’s Treprostinil Injection sales; Liquidia has since ended that promotion agreement.

revenue
SegmentShareRevenue
Product sales, net
Sold outright

94%
Service revenue, net
6.3%

Who Are Their Customers?

Liquidia sells YUTREPIA to specialty pharmacies and a specialty distributor, which in turn sell it to patients, clinics, hospitals, and federal healthcare programs. Its field force also calls on healthcare providers and distribution and reimbursement stakeholders.

Do Revenues Turn Into Profits?

No. It lost $68.9M in FY2025.

Operating income, FY2025
−32% of revenue
▲ +58% (Loss) vs FY2024 (−$121.3M, −867%)
Net income, FY2025
−44% of revenue
▲ +46% (Loss) vs FY2024 (−$128.3M, −917%)
Free cash flow, FY2025
−25% of revenue
▲ +59% (Loss) vs FY2024 (−$98.4M, −703%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +315%
vs $54.3M in Q3 FY2025
Net income
▼ −6589% (Loss)
vs −$3.5M in Q3 FY2025
Product sales, net share of revenue vs 95.1% in Q3 FY2025
  • Oct 8, 2026 Agreed to settle litigation and remove YUTREPIA’s PH-ILD indication The agreement allows continued marketing for PAH, ends Liquidia’s Sandoz promotion agreement for Treprostinil Injection, and requires it to stop promoting YUTREPIA for PH-ILD.

Growing. Revenue grew 12.3x in 4 years, from $12.9M in FY2021 to $158.3M in FY2025, about 87% a year.

YUTREPIA launch The older report described YUTREPIA as a lead candidate with tentative FDA approval; the latest says it received approval and began commercialization, shifting it from a candidate awaiting approval to a marketed medicine.

Revenue over time
Product sales, net Service revenue, net
$200M$100M$0

Who Do They Compete With?

Competes with Johnson & Johnson, Gilead Sciences, Bayer Schering Pharma, Merck &, United Therapeutics, MannKind, Actelion, Teva, Par Pharmaceutical, Dr. Reddy’s, Alembic, Corsair Pharma, and Insmed

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support